JSLLJeena Sikho Lifecare Ltd.

    Jeena Sikho Lifecare incorporates Ayugenomics for genomics and Ayurveda research

    • Mergers & acquisitions
    • Ayurveda

    Jeena Sikho Lifecare (NSE: JSLL) has incorporated Ayugenomics Private Limited as a subsidiary to carry on research, development, testing, diagnostics and clinical services combining genomics with Ayurveda and other AYUSH systems of medicine, it said in a filing on 11 Nov 2026. The company holds 60% of the subsidiary's equity.

    The subsidiary's stated business and capital

    Ayugenomics Private Limited was incorporated in India under the Companies Act, 2013 on 11 Nov 2026, with CIN U72100DC2026PTC476416. The filing describes its objects as research, development, testing, diagnostics and clinical services that combine genomics and allied omics sciences with Ayurveda and other AYUSH systems of medicine.

    The stated objects also include genomics-based tests and software, clinical studies, herbal nutraceutical and botanical products, wellness and training programmes, and work with hospitals and governments in India and overseas, including Japan. The subsidiary will seek patents and approvals from bodies including CDSCO and the US FDA.

    The authorised share capital is ₹5,00,000 divided into 50,000 equity shares of ₹10 each. The company subscribed for 30,000 equity shares, paying ₹3,00,000 by cash through banking channels, which the company says was approved by its Board. Managing Director Manish Grover is a director of the subsidiary, and the shares were subscribed at face value, described as arm's length. The subsidiary has not commenced business operations.

    How it fits the company

    The company's earlier intimation of 4 Nov 2026 covered the approval for this incorporation. The company's latest reported quarter, Q1 FY27, showed consolidated total income of ₹238.73 crore and net profit of ₹65.89 crore, and its market value was ₹4,506 crore at the 11 Nov 2026 close. The initial capital of ₹3,00,000 is small against those figures.

    What the subsidiary means for Jeena Sikho Lifecare's shareholders

    The company puts in ₹3,00,000 of initial equity, and the filing describes no approvals required for the incorporation itself. The filing does not say how the subsidiary will be funded beyond that initial amount, when it will start business, or how its work differs from the company's existing business.

    At a glance

    ItemDetail
    SubsidiaryAyugenomics Private Limited
    Incorporated11 Nov 2026
    Initial capital₹3,00,000 for 30,000 equity shares of ₹10 each
    Holding60%
    Stated businessGenomics combined with Ayurveda and AYUSH research, diagnostics and clinical services

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Jeena Sikho Lifecare Ltd. articles